Teachers Retirement System of The State of Kentucky acquired a new stake in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 415,100 shares of the biopharmaceutical company's stock, valued at approximately $24,225,000. Teachers Retirement System of The State of Kentucky owned 0.07% of Royalty Pharma as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Provenance Wealth Advisors LLC bought a new position in shares of Royalty Pharma in the 3rd quarter worth $26,000. CoreCap Advisors LLC increased its holdings in shares of Royalty Pharma by 89.2% during the 2nd quarter. CoreCap Advisors LLC now owns 876 shares of the biopharmaceutical company's stock valued at $49,000 after purchasing an additional 413 shares in the last quarter. Bessemer Group Inc. increased its stake in shares of Royalty Pharma by 34.7% in the 1st quarter. Bessemer Group Inc. now owns 1,094 shares of the biopharmaceutical company's stock valued at $53,000 after purchasing an additional 282 shares in the last quarter. Root Financial Partners LLC purchased a new position in Royalty Pharma during the third quarter valued at $62,000. Finally, Mitsubishi UFJ Morgan Stanley Securities Co. Ltd. acquired a new stake in shares of Royalty Pharma in the third quarter worth approximately $63,000. Hedge funds and other institutional investors own 54.35% of the company's stock.
Analyst Upgrades and Downgrades
RPRX has been the subject of a number of recent research reports. Zacks Research raised Royalty Pharma from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, November 11th. Morgan Stanley boosted their target price on shares of Royalty Pharma from $65.00 to $67.00 and gave the stock an "overweight" rating in a research note on Wednesday, October 7th. JPMorgan Chase & Co. boosted their target price on Royalty Pharma from $58.00 to $62.00 and gave the company an "overweight" rating in a report on Friday, August 7th. Bank of America reissued a "buy" rating on shares of Royalty Pharma in a report on Wednesday, August 5th. Finally, Wall Street Zen raised Royalty Pharma from a "buy" rating to a "strong-buy" rating in a report on Saturday. One research analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. According to MarketBeat, Royalty Pharma has an average rating of "Buy" and a consensus target price of $63.29.
Read Our Latest Stock Analysis on Royalty Pharma
Royalty Pharma Stock Down 1.1%
Shares of NASDAQ:RPRX opened at $68.53 on Tuesday. The firm has a market cap of $39.40 billion, a price-to-earnings ratio of 57.11, a PEG ratio of 1.37 and a beta of 0.37. The company has a current ratio of 1.29, a quick ratio of 1.29 and a debt-to-equity ratio of 0.77. The stock's 50-day moving average price is $61.61 and its two-hundred day moving average price is $54.67. Royalty Pharma PLC has a 12-month low of $37.31 and a 12-month high of $70.37.
Royalty Pharma Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a $0.2350 dividend. This represents a $0.94 dividend on an annualized basis and a dividend yield of 1.4%. The ex-dividend date of this dividend is Friday, November 13th. Royalty Pharma's dividend payout ratio (DPR) is currently 78.33%.
Insider Buying and Selling
In related news, EVP Marshall Urist sold 4,126 shares of the firm's stock in a transaction on Monday, October 5th. The shares were sold at an average price of $57.10, for a total transaction of $235,594.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Christopher Hite sold 100,000 shares of the company's stock in a transaction that occurred on Tuesday, September 22nd. The shares were sold at an average price of $58.53, for a total value of $5,853,000.00. Following the completion of the transaction, the executive vice president directly owned 270,401 shares in the company, valued at approximately $15,826,570.53. The trade was a 27.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 108,252 shares of company stock worth $6,327,407 in the last quarter. Insiders own 18.84% of the company's stock.
Royalty Pharma Profile
(
Free Report)
Royalty Pharma plc is a biopharmaceutical royalty company that provides funding to companies and inventors in exchange for royalty interests in medicines. It acquires existing royalties and helps finance drug development and commercialization through royalty-based transactions and other forms of funding. The company's portfolio includes royalty interests in medicines across a range of therapeutic areas, spanning both approved treatments and products in development. Royalty Pharma generally earns revenue when these medicines are sold; it does not operate as a conventional drug manufacturer or commercialize medicines itself.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Royalty Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Royalty Pharma wasn't on the list.
While Royalty Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.